182 SharmaA.ChablozS.LapidesR
doi: 10.1002/art.1780371106
medical weight loss clinics market was valued at approximately $1.17 billion in 2024 and is projected to reach $1.50 billion by 2030
4 Discussion Current evidence strongly supports the efficacy of GLP-1 receptor agonists for inducing substantial weight loss, improving metabolic control, and reducing cardiovascular risk often surpassing the short-term effects of exercise alone ( Exercise and lifestyle interventions, while generally less potent for weight loss, provide unique and irreplaceable health benefits preserving skeletal muscle, improving cardiorespiratory fitness, enhancing psychological well-being, and lowering chronic disease risk ( Hybrid care models that integrate pharmacotherapy with behavioral support are emerging as the most promising framework for sustainable obesity and diabetes management ( Persistent challenges include the high cost and limited accessibility of GLP-1RAs, variable long-term adherence, and a lack of long-term data on sustainability, relapse rates, and overall health outcomes
Clinical context: SURMOUNT-1 showed tirzepatide produced an average of 22.5% body weight loss at 72 weeks at the highest dose
doi: 10.1002/14651858.CD010223.pub2, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 65
